Advancing Gastroenterology from the Frontlines of Patient Care

Therapeutic innovation in gastroenterology has accelerated over the past decade, reshaping how clinicians evaluate treatment response, define success, and identify unmet needs across inflammatory and metabolic diseases. As the armamentarium expands, so too does the complexity of decision-making in both inflammatory bowel disease (IBD) and broader digestive disorders. The question is no longer whether options exist, but how to deploy them effectively—and when to pivot.

In the accompanying video, Benjamin McDonald, MD, PhD, a gastroenterologist specializing in inflammatory bowel diseases at UChicago Medicine, explains that early identification of suboptimal response remains grounded in careful clinical reassessment. In the absence of predictive biomarkers that reliably match individual patients to specific agents, clinicians must synthesize disease severity, distribution, comorbidities, and patient preferences. Clinical trial data provide practical benchmarks—particularly regarding expected timelines for response. Some therapies demonstrate benefit within weeks, whereas others may require months, informing when optimization or switching should be considered.

From a broader specialty perspective, Russell Cohen, MD, professor of medicine at the UChicago Medicine, noted that 2025 marked a banner year for guideline development across ulcerative colitis, metabolic liver disease, and gastrointestinal bleeding. Institutional leadership in translational research continues to bridge laboratory discovery and bedside application, reinforcing the importance of evidence-based adaptation as new mechanisms of action emerge.

McDonald anticipates that emerging therapies—including anti-fibrotic strategies in Crohn disease—may necessitate new monitoring paradigms. While core goals remain unchanged—symptom control, mucosal healing, and durable remission—success metrics may expand as clinicians begin treating disease phenotypes previously managed surgically.

Cohen highlighted additional clinical lessons from 2025, including the growing use of combination biologic strategies to overcome therapeutic ceilings and the expanding investigation of glucagon-like peptide-1–based agents beyond metabolic indications. Looking ahead, both physicians identified precision medicine and microbiome-directed interventions as critical areas for trial development. Cohen emphasized prevention as a particularly underexplored frontier, including efforts to identify microbiome alterations preceding overt disease.

Together, their perspectives underscore a shared priority: refining therapeutic sequencing, improving patient-specific targeting, and designing clinical trials that better anticipate real-world complexity while advancing measurable, durable outcomes in digestive disease care.